Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Aims and scope
Articles
-
-
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
-
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion
-
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
-
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
-
Breast cancer brain metastases: the last frontier
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
-
The development of bispecific antibodies and their applications in tumor immune escape
Editors-in-Chief
Zihai Li, The Ohio State University
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical Colleg
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Follow
Annual Journal Metrics
-
Speed
34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publicationCitation Impact
3.492 - 2-year Impact Factor
0.709 - Source Normalized Impact per Paper (SNIP)
0.941 - SCImago Journal Rank (SJR)
Usage
174,663 Downloads
48 Altmetric Mentions
On the blog
-
MIRRORS: robotic surgery for advanced ovarian cancer
19 February 2021
-
-
